Abstract: Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.

Keywords: Cancer therapy, controlled delivery, nanoparticles, nitric oxide donors, nitric oxide releasing biomaterials, nitric oxide.

1. INTRODUCTION

Although the therapeutic applications of glyceryl trinitrate (GTN) have been established for over 165 years, until the 1980s little was known about GTN’s physiological mechanism of action [1, 2]. Then the pioneering research of Furchgott, Ignarro, Murad and Moncada identified nitric oxide (NO) as the endothelium-derived relaxing factor [3, 4]. NO is a multifunctional free radical, with a molecular weight of only 30 Da, which has an unshared electron in its outer shell. As a simple diatomic free radical, NO is a short-lived molecule with a half-life ($t_{1/2}$) between 0.1 to 5s in aqueous solutions, and in vivo its levels are continuously modulated by the nitric oxide synthases (NOS) [5]. Its $t_{1/2}$ in aqueous solutions is approximately nine fold shorter compared to hydrophobic solvents and this is mainly due to the autoxidation reaction which occurs in the presence of oxygen [6]. Due to NO’s lipophilicity it can readily diffuse through cell membranes and, under physiological conditions, its diffusion constant is similar to molecular oxygen [7, 8].

As a signaling molecule NO regulates key physiological processes, such as gene regulation, vasorelaxation, vascular permeability, bronchodilation, platelet aggregation, angiogenesis, neuronal communication, hormone secretion, inflammation, gastrointestinal mobility and wound healing [9, 10]. The over or under-production of NO causes or
Pharmaceutical Nanotechnology, 2019, Vol. 7, No. 4

contributes to several pathophysiological conditions including cancer [11]. Over the past decades there have been extensive efforts to investigate the effects of NO on cancer biology, however, the findings are controversial. Overall NO has been termed a double edged sword, as it has both tumoricidal and tumor promoting effects. The concentration and duration of its presence at a particular site are thought to play a prominent role in cancer biology [12].

Inhaled NO is now recognized as an invaluable tool for decreasing pulmonary inflammation, neonatal pulmonary hypertension, and for heart and lung surgery. Beyond these applications it has limited, if any, other clinical value due to its low water solubility, instability and inconvenient handling of authentic aqueous solutions of NO [13-15]. Hence, there has been increasing interest in the development of NO releasing compounds to generate NO in situ.

For cancer therapy the utility of authentic aqueous solutions of NO, and most currently available NO donor agents (consisting of low molecular weight molecules), is highly limited due to their low half-lives, instability under physiological conditions, rapid systemic clearance, unspecific NO release and NO-independent toxicities. With the emergence of nanotechnology, the application of intelligent biomaterials to the controlled delivery of NO has emerged as a unique strategy for tumor targeting.

Herein we discuss the role of NO in cancer biology, and the therapeutic use of NO releasing functional groups, with a focus on the six main groups: organic nitrates, organic nitrites, metal complexes, sydnonimines, diazeniumdiolates, and S-nitrosothiols. We also review current advances in the design of NO releasing biomaterials and their applications for tumor therapy.

2. THE BIOLOGICAL ACTIONS OF NO

The biological actions of NO can occur via direct or indirect chemical reactions. The best characterized example is of NO directly binding to metal complexes of different proteins to form metal nitrosyl complexes, regulating their biological activity [16]. For example, NO reacts with soluble guanylate cyclase (sGC) at its haem moiety; upon binding the enzyme is activated, enabling the catalytic transformation of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Downstream of this event kinase-mediated signal transduction proteins responsive to cGMP are activated, such as protein kinase G (PKG). This has been recognized as the principal pathway by which NO mediates many physiological processes including: smooth muscle relaxation, neurotransmission, inhibition of platelet aggregation and adhesion [17]. For the classical mechanism suggested for vasodilatory effects of NO, PKG sequesters calcium (Ca\(^{2+}\)) into intracellular stores via stimulation of the sarco-endoplasmic reticulum Ca\(^{2+}\) ATPase (SERCA), thereby decreasing cytoplasmic Ca\(^{2+}\) concentration which inhibits the cell’s contractile apparatus [18] through interactions with myosin (Fig. 1). NO-mediated vasodilation also occurs via inhibition of Ca\(^{2+}\)-dependent K\(^{+}\) channels [19]. Inhibition of such channels, which are specifically important in cerebral vasodilatation [20], results in depletion of cellular calcium and therefore relaxes the vascular muscle.

In addition to metal binding, NO may also undergo chemical reactions with a variety of endogenous radical species, producing reactive nitrogen species, which are responsible for additional signaling roles and certain types of NO-mediated toxicity in vivo. For instance, the reaction of NO with O\(_2\) or the superoxide anion (O\(_2\)\(^{-}\)) produces nitrogen dioxide (NO\(_2\)) and peroxynitrite (ONOO\(^{-}\)) respectively [21]. These reactive species act as potent oxidizing and nitrating agents [21] which can result in changes to DNA, lipid peroxidation, and protein modifications via nitrification, nitrosative and oxidative reactions (Fig. 1) [22].

3. NO IN CANCER BIOLOGY

The role of NO in tumor therapy is diverse. Depending on both the concentration and duration of NO action within the tumor cells, it can affect cancer initiation, enhance cell progression, tumor blood flow, angiogenesis, metastasis, and apoptosis, cell death and tumor suppression (for reviews see [9, 23, 24]). The targeted release of NO may also provide opportunities for cancer therapy and enhance the efficacy of chemotherapeutic and radiotherapy, provided that the appropriate concentration of NO reaches the tumor [24].
Vannini et al. have recently categorized the concentration of NO in tissue as low (50-100 nM), intermediate (100-400 nM) or high (400-1000 nM) [25]. At low and intermediate concentrations, NO normally stimulates cancer cell progression, prevents apoptosis and enhances angiogenesis and metastasis via various signaling pathways which are crucial for tumor cell survival, such as the extracellular signal-regulated kinase (ERK), Akt, mammalian target of rapamycin (mTOR), Ras and epidermal growth factor receptor (EGFR) pathways [23]. Higher concentrations of NO are recognized as having an anti-tumor effects by inducing apoptosis and sensitizing tumors to chemotherapeutic and radiotherapy [24], however the exact mechanisms responsible for establishing different NO activities are unknown. It appears that there is a gradation of NO effectiveness in activating these different pathways [26-28] (Fig. 2). For example, stimulation of MCF-7 breast cancer cells, macrophages, or endothelial cells with activation of PKG, increased ERK-P and Akt-P expression at low nM levels of NO (10-60 nM). Increased hypoxia-induced factor I alpha (HIF-1α) expression was then detected at approximately 100 nM NO [29, 30], while p53 expression was associated with higher levels of NO that led to apoptosis [31]. In addition, NO is known as a physiological regulator of mitochondrial respiration [32]. At both low and high concentrations it inhibits mitochondrial respiration by different mechanisms [32]. At low concentrations NO inhibits cytochrome c oxidase in competition with oxygen, and this process is fully reversible [33]. Probably by nitrosating or oxidising thiol centers of proteins and reacting with the iron-sulfur centers, at high concentrations NO inhibits the respiratory chain complexes I, II and V, as well as creatine kinase [32]. This results in depolarization of the mitochondrial membrane and induces swelling and calcium release [34].

Due to the complexity of the signaling pathways involved, NO administration may result in different effects on cancer. For example, S-nitroso-N-acetyl-DL-penicillamine (SNAP) inhibited cell proliferation in umbilical vein endothelial cells [35], while in mouse clonal osteogenic cells it stimulated cell proliferation [36]. In addition, the expression of NOS has been investigated in several *in vitro* and *in vivo* cancer studies (for review see [25]). In animal models, depending on the tumor microenvironment and the tumor type, NOS overexpression resulted in tumorigenic or anti-tumor effects [37-39]. Similarly, it has both pro- and anti-metastatic effects [40]. In metastasis, epithelial cells lose normal cell-cell adhesion and gain mesenchymal markers which promote cell...
migration and invasion, a process known as epithelial to mesenchymal transition (EMT) [41]. Emerging evidence has shown that the NF-κB family of transcription factors are pivotal regulators of both promoting and maintaining an invasive phenotype [42]. Several studies have shown that a high level of NO, delivered via NO donors such as diethylenetriamine NONOate (DETA/NO), inhibits the EMT phenotype in metastatic cancer cell lines by dysregulation of NF-κB [43, 44]. However others have reported that NO facilitated the induction of MET and tumor invasion [45].

4. DRUG DELIVERY SYSTEMS AND EFFECTS OF NO ON EPR BASED ANTICANCER-DRUG DELIVERY

In cancer therapy, biomacromolecules larger than 40 kDa have been developed as drug carriers to promote tumor targeting. The macromolecules that are traditionally used for drug delivery systems (DDS) include; liposomes, polymeric nanoparticles, micelles, dendrimers and inorganic nanoparticles made of iron oxide, gold, quantum dots or metal oxide frameworks [46-48].

The tumor vasculature is structurally and functionally abnormal [49]. The vessels spread chaotically with abnormally varied caliber, and the smooth muscle layer is not correctly formed. Hence vascular walls contain wide fenestrations [50-53]. Furthermore, tumor tissues have inefficient lymphatic drainage [54]. A significant number of vessels make shunts between arterial and venous ends, effectively stealing blood from regions of the tumor tissue and inducing localized hypoxia [53, 55, 56].

This leaky tumor vasculature, slow venous return and poor lymphatic clearance lead to the accumulation of macromolecules within the tumor, and this phenomenon was termed the enhanced permeability and retention (EPR) effect of macromolecules (larger than 7 nm) by Maeda and colleagues [57].

Despite the remarkable advances in DDS based on EPR, a limited number of nanocarriers have reached the clinic so far [58]. In this context, one major challenge is the lack of an EPR effect for macromolecules in the hypoxic area of tumors, particularly the necrotic regions of primary and metastatic cancers [59, 60]. Therefore extensive efforts have been made to increase the EPR effect in tumor tissue [61].

Several factors affecting vascular permeability have been investigated, including: vascular endothelial growth factors, bradykinin, prostaglandins and NO [62], as any intervention which enhances tumor blood supply should increase the EPR effect of macromolecules. For example, the NOS inhibitor Nω-monomethyl-l-arginine (NMMG), was shown to suppress vascular permeability and hence the EPR effect [63], while NO donors have been found to potentiate the EPR effect. Examples of potentiation include the local administration of the NO donor GTN directly into tumor sites, which increased the concentration of PEG-conjugated zinc protoporphyrin IX anticancer NPs, indicating an elevated EPR effect and thereby improved delivery of the drug to the tumor [64]. Similarly, infusion of isosorbide dinitrate (ISDN) into the local feeding artery of tumours enhanced
the site-specific delivery of anticancer NPs in humans [61].

EPR enhancement can also be achieved by elevating blood pressure, as this will increase tumor blood flow [59], and several clinical studies have used NO donors such as GTN to improve the responsiveness of tumors to chemo and/or radiotherapy (Table 1). On the other hand, the systemic administration of unstable NO donors may result in a significant decrease in systemic blood pressure thereby decreasing the EPR effect [59]. Therefore, the utility of NO donors to enhance the EPR effect in solid tumors, or to reach a tumorcidal level of NO, is highly dependent on the stability of the NO donors.

In addition, as mentioned above, NO acts differently over a range of concentrations within the tumor, and therefore it must be delivered at a designated concentration to tumor cells. Hence, the development of stable and tuned NO releasing compounds are required for applications towards tumor therapy. In the following sections we initially review the NO donor moieties which can be used for controlled delivery of NO, and then focus on recent developments in the controlled delivery of NO using NO releasing macromolecules for tumor therapy.

5. MAJOR CLASSES OF NO DONORS

There are at least 16 families of NO precursor and direct NO donors with remarkably varied chemical reactivities and NO-release kinetics. However, organic nitrates, organic nitrates, metal complexes, sydnonimines, diazenio-diolates, and S-nitrosothiols are the major groups used in experimental and clinical applications.

5.1. L-Arginine and N-Hydroxyguanidine

NO is synthesized via conversion of L-arginine to NO and citrulline by the NOS family (Scheme 1). There are three different NOS isoforms in mammalian organisms: neuronal (nNOS), inducible (iNOS), and endothelial NOS (eNOS). The isoforms have similar mechanisms for NO synthesis however, their distribution in different cell types, and their mechanism of activation, are different [65]. nNOS and eNOS are mainly expressed in neuronal and endothelial cells respectively, but iNOS is expressed in both endothelial as well as nonvascular cell types such as macrophages, fibroblasts, and hepatocytes [66]. A major functional difference between NOS isoforms is that the activity of iNOS is initiated in response to inflammatory mediators and the expression of iNOS in healthy states is absent. Therefore, the activity of iNOS is subject to protein transcription, and the expression of iNOS has been shown to be a detrimental player in the development of disease. Whereas eNOS is constitutively active and regulates physiological processes such as vasodilation [66].

Although it is not an actual NO donor, L-arginine administration has been widely used to increase NO generation. For example, it displays beneficial properties in stroke [67, 68], angiogenesis [69] and wound healing [70]. The biosynthesis of NO is an oxygen dependent pathway, and so analogues of the intermediate generated during NO synthesis, the N-hydroxyguanidines such as ω-hydroxy-L-arginine (NHA) [2], have been used as an alternative for L-arginine delivery [71]. This family is particularly important in the treatment of hypoxic conditions such as stroke, as converting NHA to NO can occur at low oxygen concentrations [72].

5.2. Organic Nitrates

Organic nitrates (RONO2) are nitric acid esters of alcohols. They are the oldest class of NO donors and currently the most commonly used NO donor drugs [73]. Organic nitrates can be synthesized by esterification of the corresponding alcohols, or by the reaction of alkyl halides with AgNO3 (Scheme 2) [2]. GTN, isosorbide mononitrate (ISMN), pentaerythritol tetranitrate (PETN) and nicorandil are the most widely used examples in clinical studies. Most organic nitrates are highly stable, and the mechanism by which they release NO is not fully understood. However, it has been suggested that the NO formation can happen via both enzyme-dependent and non-enzymatic pathways [2]. Several enzymes such as NADPH-dependent cytochrome P450 [74, 75] and certain isoenzymes of the glutathione-S-transferase (GST) family [76] have been recognized in the bio-activation of organic nitrates. It has been shown that thiols significantly affect both in vitro
Table 1. Example clinical studies which used NO donors to improve the effects of chemo and/or radiotherapy.

| Drug                                      | NO Donor           | Type of the Study | Cancer Type          | Results                                                                 | References |
|-------------------------------------------|--------------------|-------------------|----------------------|-------------------------------------------------------------------------|------------|
| Cisplatin and irinotecan                  | Isosorbide mononitrate (ISMN) | Phase II clinical trial | Non-small cell lung cancer | ISMN did not improve the treatment outcome of the chemotherapy          | [174]      |
| 5-FU and radiation                        | GTN patch          | Phase I clinical trial | Lung cancer          | The patches were well-tolerated and significantly enhanced the efficacy of the treatment. | [175]      |
| Combination of vinorelbine and cisplatin  | GTN                | Phase II clinical trial | Non-small cell lung cancer | Improve overall response in patients with stage IIIB/IV NSCLC patients | [176]      |
| Vinorelbine, cisplatin and concurrent radiotherapy | GTN patch          | Phase II clinical trial | Non-small cell lung cancer | Increase in the overall survival of compared patient after 2 years | [177, 178] |
| Prostate-specific antigen (PSA)           | GTN patch          | Phase II clinical trial | Prostate cancer      | Significantly (p<0.001) longer doubling PSA time (31.8 months)          | [179]      |
| Transcatheter arterial chemoembolization  | GTN                | Clinical trial     | Liver cancer         | GTN improved the delivery of tumor-targeted therapy via enhanced permeability and retention. | [180]      |

Scheme 1. The mechanism of NO biosynthesis.

Scheme 2. Some examples of the most commonly used organic nitrates and their general mechanism of synthesis. The nitrate group is highlighted (blue).
and in vivo responses to GTN by promoting its NO release [77, 78] however these reactions are much slower than enzymatic activation. Therefore the dependency on enzymatic reaction to liberate NO is a major drawback to the clinical use of these drugs, as tolerance develops over time [79].

The organic nitrates have several established clinical applications. GTN is used as a cheap and effective drug for the rapid reversal of pain associated with acute angina [80, 81], and also occasionally for heart failure [82]. ISMN, which is a slower NO-releasing member of the organic nitrate family, has been used in the treatment of chronic angina [83]. As well as providing rapid and sustained dilation of veins, reducing cardiac afterload work, it causes dilation of cardiac vessels, which restores oxygen supply to ischemic cardiac muscle.

5.3. Organic Nitrites

Analogous to nitrates, organic nitrites are esters of alcohols and nitrous acid. They are mainly synthesized via reacting alcohols with nitrous acid or other nitrosating agents, as well as by the reaction of alcohols with gaseous NO (Scheme 3) [2]. The nitrosyl nitrogen atoms in organic nitrites are highly electronegative, which results in electron deficiency, hence they are highly prone to nucleophilic attack, which results in trans-nitrosation between the organic nitrite and the nucleophile [84]. Butyl nitrite (BN), isobutyl nitrite (ISBN), tert-butyl nitrite (TBN), amyl nitrite (AMN), and isoamyl nitrite (IAMN) have been used as vasodilators in the clinic.

It has been shown that organic nitrites activate NO signalling pathways, relaxing pulmonary vessels and decreasing blood pressure [85]. The release of NO from organic nitrites can occur through S-nitrosothiol formation due to the very fast trans-nitrosation with sulphydryl groups [84]. Despite the higher potency of organic nitrites (as they are more reactive and less dependent on enzymatic activation) they are not as commonly used as organic nitrates due to their cytotoxicity [2], however AMN and BN have frequently been used in the treatment of angina pectoris [86]. The advantage of the organic nitrites is that they are less susceptible to inducing drug tolerance in comparison to organic nitrates such as GTN [87]. However a lack of selectivity and bioavailability, as well as cytotoxicity and carcinogenicity, restrict the applications of this class of NO donor [86].

5.4. Metal Complexes

NO is a strong ligand in metal complexes, and its binding constant is normally much higher than those of CO and O₂ [88]. Numerous metal centers (primarily iron) react with NO to give adducts (Scheme 4), and the primary mechanism by which NO regulates many signaling pathways is through binding to metal centers, such as the haem group or iron-sulfur clusters of proteins. NO, as a ligand in metal complexes, has various oxidation states from M-NO⁻ to M-NO⁺ and the oxidation state
determines the reactivity of NO in the complex [89]. For example NO in sodium nitroprusside (SNP, Na₂[Fe(CN)₅NO]) exhibits significant NO⁺ character and iron has an oxidation state of Fe³⁺. The NO ligand is therefore subject to nucleophilic attack, hence the rate of NO release from SNP can be affected by thiols and other potential nucleophiles in the environment.

![Scheme 4. Example structures of NO releasing metal complexes, and the mechanism of SNP synthesis.](image-url)

SNP was the first metal-NO compound discovered over 150 years ago, and has been in widespread clinical use for 40 years [90]. SNP is used as an arterial and venous vasodilator in cardiac surgery, hypertensive crisis, heart failure, vascular surgery, and pediatric surgery [91]. However, SNP degradation is accompanied by five equivalents of cyanide release, which results in "cyanide toxicity" [91]. This dose limiting toxicity of cyanide release has been well-documented in several clinical cases and animal studies and precludes long term administration [92, 93].

In addition to iron, ruthenium (Ru) also has a high affinity for NO, and this has resulted in the development of a family of photoactive NO-releasing Ru complexes [94]. By modification of the π-bonding of other ligands, the affinity of Ru for NO can be modified, thereby regulating NO release from the complex [95]. Several photoactive Ru nitrosyls have been tested in in vitro and in vivo studies for controlled NO delivery [96]. However, efficient NO release requires high power UV light (300-400 nm) which is harmful to tissues [94] and this hurdle has prevented the translation of this family of NO donors into clinical use.

### 5.5. Diazoeniumdiolates

The diazeniumdiolates (also known as ‘NONOates’) consist of a diolate group attached to a primary or secondary amine or polyamine. In solid form they are stable, but decompose spontaneously in solution at physiological pH and temperature to generate two equivalents of NO per diolate [97]. They can be simply synthesized by exposing a primary or secondary amine to NO under high pressure [98], and depending on the structure of parent amine, temperature, and pH, their decomposition rates vary from seconds to hours [99]. Unlike most other NO donors, the NO release of diazeniumdiolates is not catalyzed by cellular metabolites or enzymes, and follows first-order kinetics. Hence the duration of action of the drugs can be directly predicted from their rates of decomposition in vitro. In addition, independent NO release explains the lack of tolerance experienced with these compounds [100]. Some of the most studied NONOates are methylamine hexamethylene methylene NONOate (MAHMA/NO), diethylamine NONOate (DEA/NO), spermine NONOate (SPER/NO), proli NONOate (PROLI/NO) and diethylenetriamine NONOate (DETA/NO) (Scheme 5). No drug from this class of NO donors has advanced to clinical stages, however, they have frequently been tested in various experimental models of cardiovascular disease [97] mainly as supplementary treatments for vital cardiovascular operations such as balloon angioplasty and bypass, to prevent thrombosis and neointimal formation [101-105].

### 5.6. Sydnonimines

Sydnonimines are another class of NO releasing agents which, due to the concomitant generation of O₂⁻ and NO, are recognized as an ONOO⁻ donors [106, 107]. In general, sydnonimines are synthesized by α-cyanoalkylation of dialkylhydrazines followed by nitrosation under acidic conditions (Scheme 6). 3-morpholinosydnonimine (SIN-1) and its precursor molsidomine (N-ethoxycarbonyl-3-morpholinosydnonimine) are the most exen-
Scheme 5. Chemical structures of representative NONOates and their mechanism of synthesis. The diazeniumdilolate moiety is highlighted (blue).

Scheme 6. Chemical structures of sydnonimines and their mechanism of synthesis.

sively studied compounds of this class. N-acyl derivatives of sydnonimines in solid form are stable and in the absence of light can be kept at room temperature. Sydnonimines can be degraded by both enzymatic and nonenzymatic processes at physiological pH. Nonenzymatic hydrolysis is accelerated by alkaline pH, the presence of O₂, and light. The enzymatic deacetylation and conversion of molsidomine to SIN-1 occurs primarily in the liver, SIN-1 then spontaneously decomposes to NO and O₂⁻ in the blood [108, 109]. As ONOO⁻ is highly reactive, it is believed that many of the actions of sydnonimines are mediated via cGMP-independent pathways, and possibly activation of K⁺ channels [110]. One of the main advantages of molsidomines as NO donors is the absence of tolerance. Hence, in the early 1980s, sydnonimines were widely studied as alternatives to organic nitrates in stable angina, and in the treatment of coronary heart disease [109]. However, they failed to show clear benefit in many large-scale clinical trials [111].

5.7. S-nitrosothiols

S-nitrosothiols (SNTs), also known as thionitrites, are an important class of NO donor which are mainly synthesized by the reaction of a thiol with a nitrite. SNTs, with certain exceptions,
are very unstable compounds in aqueous solution, especially the primary and secondary SNTs [112]. Degradation of SNTs involves both homolytic and heterolytic cleavage of the S-NO bond [113] which results in the corresponding disulfide and NO, NO⁺ or NO⁻ (Scheme 7). Homolytic cleavage is a two-step reaction which starts by cleavage of S-NO bond to make the thyl radical (RS•), followed by reaction of two RS• radicals to form a disulfide (RSSR) [114]. One of the main reasons why tertiary SNTs are more stable than primary and secondary analogues could be due to the easier dimerization of the less sterically hindered RS•. The degradation of SNTs may also occur through trans-nitrosation to other nucleophilic species, such as thiols, without the appearance of NO as a free entity [113].

The instability of SNTs in vivo is more pronounced, as their degradation rate is accelerated by vitamin C, trace amounts of metal ions, thiols such as GSH, and oxygen, as well as by enzymatic cleavage.

S-nitrosoglutathione (GSNO), N-acetylpenicillamine (SNAP), trityl S-nitrosothiol, (Ph₃SNO) and tert-butyl S-nitrosothiol (tButSNO) are the most commonly studied SNTs [114], alongside the recently developed tert-dodecane S-nitrosothiol (tDodSNO) [115] (Scheme 7).

5.8. Other NO-Releasing Moieties

N-nitrosamine, N-hydroxy nitrosamine, nitrosimine, furoxan and oximes are other functional groups which can serve as NO releasing moieties. However the majority of studies still rely upon the six main classes of NO donors.

One of the most important drugs which contains the N-nitrosamine group is N-methyl-N-nitrosourea streptozocin (STZ), which has antitumor as well as diabetogenic and carcinogenic activities [2]. NO release by STZ in the pancreatic β cell is known as one of the central mechanisms for these properties [116]. β cells of the pancreas are sensitive to NO and ROS as they possess low levels of ROS scavenging enzymes [117], and overproduction of NO damages the DNA content of the cells. N-hydroxy-N-nitrosamines are potent anti-hypertensive and anti-coagulative agents which are heat-stable in solution. Cupferron, alanosine, and dopastin are the most studied compounds in this class of NO donor, which have mainly been investigated as anticancer drugs [118].

Furoxans generally are stable compounds against thermal degradation, acids and electrophiles but not toward bases and nucleophiles [2]. Their degradation and NO release take place in the presence of thiols. They currently have no clinical application, but in animal studies, some furoxans such as C92-4609, and C93-4759 displayed tolerance-resistant vasodilation [119, 120].

6. HYBRID NO-RELEASING ANTICANCER DRUGS

Due to the diverse activity of NO in biological processes, as well as the complexity of NO delivery to tumor tissue, low molecular weight NO releasing compounds have made limited progress for tumor treatment so far. In particular, short half-lives, non-specific NO release, and rapid systemic clearance have hindered the clinical development of most NO donor compounds as anticancer drugs. However, there has been an extensive effort to develop hybrid NO donor drugs by attachment of NO donor moieties to currently available anticancer drugs to maintain the pharmacological activity of the parent drug, while gaining benefit from the biological actions of NO [121]. To get the desired biological activity (such as anticancer action) from NO release in the hybrid, the ratio of the parent drug to NO equivalents released can be varied [122]. The most commonly used NO releasing moieties for the design of hybrid drugs are S-nitrosothiols, diazeniumdiolates, furoxans, and organic nitrates.

NO releasing versions of NSAIDs have been used for cancer therapy. For example, several NO releasing hybrids of aspirin have been designed using furoxan [123], nitrate and S-nitrosothiol moieties [124]. NCX4040, synthesized by esterification of the carboxyl group of aspirin with 4-hydroxybenzyl nitrate (Scheme 8) showed 250-6,000-fold greater efficacy at inhibiting the growth of a panel of cancer cell lines [125]. NO releasing topoisomerase inhibitors have also been synthesized by conjugation of the anticancer drug doxorubicin (Dox) with a phenylsulfonyl furoxan moiety (NO-DOXO-1). These Dox analogs were
Scheme 7. Chemical structures of common SNTs, and the mechanisms of SNT decomposition. NO releasing moieties are highlighted (tertiary SNT, green; primary SNT, red).

Scheme 8. Example structures of hybrid NO releasing anticancer drugs. The parent drug (black) can be modified by NO releasing moieties (blue) and linker groups (red).
Table 2. A summary of recent examples of NO releasing NPs developed for cancer therapy, with or without combination chemotherapy.

| Functional Group | Particle                  | Study-Cancer Type                  | Combined Anticancer Agent | Stimulus for NO Release | References |
|------------------|---------------------------|------------------------------------|---------------------------|-------------------------|------------|
| NONOate          | Modified silica NP        | In vitro - ovarian cancer           | None                      | None                    | [181]      |
| NONOate          | Modified silica NP        | In vitro - non-small cell lung cancer | Cisplatin                | None                    | [182]      |
| S-nitrosothiol   | Micelle                   | In vitro and in vivo - breast cancer | Doxorubicin loaded NPs   | None                    | [144]      |
| S-nitrosothiol   | Polymeric NP              | In vitro - ovarian cancer           | Doxorubicin               | Vis light               | [169]      |
| Roussin's Black Salt | Metal silica coated NP    | In vitro - breast cancer            | Doxorubicin               | NIR-ray                 | [170]      |
| Nitrobenzene     | Polymeric NP              | In vitro – cervical cancer          | None                      | UV-ray                  | [127]      |
| S-nitrosothiol   | Silica NP                 | In vitro - cervical cancer          | Radiotherapy              | X-ray                   | [171]      |
| L-arginine       | Silica NP                 | In vitro and in vivo - pancreatic cancer | None                | Ultrasound              | [172]      |
| N-nitrosamine    | Nano-sandwich             | In vitro and in vivo - breast cancer | Doxorubicin              | UV-ray                  | [183]      |

shown to accumulate in Dox resistant human colon cancer cells (HT29-dx), and resulted in high cytotoxicity [126]. The same group has recently designed a novel light responsive NO releasing Dox to overcome multidrug resistance using a derivative of 4-nitro-3-(trifluoromethyl)aniline (NO-DOXO-2) [127].

The acetylation status of histones regulates levels of gene expression, and overexpression of histone deacetylases (HDAC) is observed in numerous types of cancer. Hence, HDAC inhibitors have been suggested as a promising agents for cancer therapy [128]. The antiproliferative activity of a NO releasing HDAC inhibitor (Scheme 8) has been reported as a superior version of vorinostat, a HDAC inhibitor drug, against the human erythroleukemia (HEL) cell line [129].

7. NO-RELEASING MACROMOLECULES

As mentioned above, so far very few low molecular weight NO releasing drugs have been used for cancer therapy whose main mechanism of action is through NO donation. Hence, in response to the need for controlled NO delivery, there has been extensive effort to design macromolecular NO-releasing vehicles [130-132]. In the following section we review the biomaterials which have been used for controlled delivery of NO particularly for cancer therapy (a few recent studies are summarized in Table 2).

7.1. Encapsulation of Gaseous NO or Low Molecular Weight NO Donors

One of the initial strategies was direct encapsulation of NO gas as an active therapeutic. Perfluorocarbon (PFC) microbubbles are emulsions of synthetic hydrophobic fluorinated hydrocarbons and surfactants which can store large amounts of O₂ and NO [133]. These emulsions are biologically inactive and can be safely injected into the vascular system [134]. It has been shown that PFC long-circulating particles can provide a physiologically significant pool of endogenous plasma NO, which can be used as a pharmacological tool for various cardiovascular complications associated with NO imbalance [135]. Polymeric carriers such as poly (vinyl alcohol) shelled NO microbubbles [136] and liposome encapsulations of gaseous NO [137] have also been investigated as NO delivery systems. Nevertheless, NO gas encapsulations are unstable and gaining control over their NO release is difficult.
Another strategy for controlled NO delivery is via the encapsulation of NO donor drugs. Here the potential advantage is that the NO donor remains trapped within the particle, avoiding unwanted cytotoxicity. For example a ruthenium nitrosyl complex was embedded in a poly-lactic-co-glycolic acid (PLGA) matrix, from which only NO release was observed with no leakage of the remaining metal fragment [138, 139].

Unlike encapsulation of gaseous NO, NO release from encapsulated NO donors is sensitive to environment, and the presence of water, vitamin C and GSH may affect the rate of NO release from the particle [130]. Recently Schoenfisch’s group has reported encapsulation of a $N$-diazeniumdioolate in liposomal structures. The NO release of the system could be precisely controlled by varying the composition of the lipid layer [140]. PROLI/NO, DEA/NO, PAPA/NO, or SPER/NO have been encapsulated in such phospholipid bilayers to form different NO-releasing liposomes [140]. The encapsulation process significantly increased the $t_{1/2}$ of the NO donors, for example, $t_{1/2}$ of SPER/NO increased from 37 min in its free form to around 2 days when encapsulated within the liposome. The physical barrier against proton diffusion/exchange provided by the lipid bilayer was demonstrated to be the main mechanism for the prolonged NO release properties of the liposomes. Interestingly, the NO-release kinetics of different liposomes with identical NO donors was dependent on the compactness of the lipid chains of each individual liposome, which is a property set upon liposome formation [140]. Therefore, by manipulation of the structure of lipid bilayer, the water permeability of the liposomes and hence the kinetics of NO release could be tuned, with tighter packing of the lipid chains decreasing the $N$-diazeniumdiolate NO donor decomposition rate (Fig. 3) [140, 141].

Recently we have designed a photoactive NO releasing nanoparticle (NP) by encapsulation of the S-nitrosothiol tDodSNO into a co-polymer of styrene and maleic acid (SMA) to afford SMA-tDodSNO. The encapsulation imparted water solubility to the highly hydrophobic tDodSNO, and protected it from degradation reactions with glutathione [142, 143]. In the absence of photoactivation, the S-nitrosothiol group within the NPs had a $t_{1/2}$ of 104 h, while photoactivation dropped this to 3.5 min. The NPs acted as a photo-switchable NO donor and induced localized vasodilation in aortic rings, and vascular hyperpermeability in mesenteric beds. When SMA-tDodSNO was co-administered with SMA-Dox (SMA NPs loaded with doxorubicin) it significantly enhanced its anticancer properties [144].
In addition, it has been shown that encapsulation of low molecular weight NONOates in liposomes improves the tumor targeting of such NO donors due to the EPR effects of the NPs [145], and administration of such NO releasing NPs with anticancer drugs increases their anticancer efficacy [144, 145].

7.2. Polymeric Organic and Inorganic NO Releasing Scaffolds

In addition, to improve the control of NO release in biological media, a wide-variety of NO donor materials such as macromolecule scaffolds, polymeric NPs, micelles, dendrimers, sol-gel derived silica NPs and surface modified metal/metal oxide NPs have been examined as NO delivery systems [130, 146]. These polymeric NO donors have been examined as treatments for a large number of pathological conditions ranging from cardiovascular diseases, wound healing, neuropathy and stroke to cancer [131, 147].

As an example of this approach, analysis of the tumor microenvironment of solid tumors has revealed that a significant part of the tumor mass is made of immune cells. Hence, tumor immune cells have been characterized as suitable targets for tumor therapy [148]. In immune cells iNOS produces high concentrations of NO, so it is possible to achieve a higher concentration of NO in tumor tissue by delivering arginine to the immune cells of the tumor [149]. Therefore there has been increasing interest in the application of poly-arginine for tumor targeting.

Kudo et al. have designed polyion complex micelles from a poly(ethylene glycol)-block-poly(l-arginine) block copolymer (PEG-b-PArg) and chondroitin sulfate for systemic anticancer immunotherapy [149] (Fig. 4). Without activation the NPs did not generate NO when exposed to iNOS in vitro. After trypsin pretreatment and hydrolysis of the polymeric Arg to monomeric arginine, iNOS exposure then resulted in NO generation. Therefore the activation of the NPs required enzymatic degradation to monomeric arginine in the lysosomes of immune or cancer cells in tumor tissue. Hence, the systemic administration of the NPs did not induce any tangible adverse effects. However they did significantly suppressed tumor growth rate in a dose-dependent manner [149].

The pivotal role of albumin in the circulation of NO in the plasma has been well established [150]. Human serum albumin (HSA) has one site of S-nitrosation at the Cys-34 thiol, which can carry NO equivalents in the circulatory system in the form of an S-nitrosothiol [150]. S-nitrosated HSA (HSASNO) has significantly superior stability compared with low molecular weight SNTs [151]. In numerous studies HSA has been used as a long-acting and safe NO donor for several pathological conditions including cancer (this has been recently reviewed [151]). As it only has one S-NO group HSASNO produced low levels of NO (nM range) when administered at physiological levels mimicking HSA in blood, therefore under pathological conditions it acts as a cytoprotective agent as it produces low concentrations of NO. To improve its NO release properties HSA has been chemically modified by attachment of linkers and then binding to low molecular weight SNTs to form poly-HSASNO. Here two HSA molecules were linked together using the amino acid linker (GGGGS)2 to form a HAS-dimer which had a significantly longer circulation time than the mono-
Fig. (5). The synthesis of NO-releasing micelles (black/blue) using GSNO (red) for synergistic cytotoxicity against cancer cells [146].

meric form of HSA [152]. It has been shown that the HSA-dimer had an enhanced accumulation in solid tumors \textit{via} an increased EPR effect [153] (Fig. 5). Nitrosation of the HSA-dimer resulted in NO releasing NPs (SNO-HSA-dimer), which also further enhanced its EPR effect in tumors [153], as well as other anti-cancer loaded NPs. In xenograft mice with B16 or C26 tumors, the SNO-HSA-dimer increased tumor accumulation of the anticancer agents N-(2-hydroxypropyl) methacrylamide (HPMA)-zinc protoporphyrin (ZnPP) and PEGylated liposomal doxorubicin (Doxil) compared with only NnPP or Doxil treated mice (by a factor of 3-4 in C26 tumors and 6 in B16 tumors), and thereby enhanced the anticancer efficacy of these drugs (Fig. 6), and increased survival of the animals [154]. The administration of SNO-HSA-dimer itself was found to be safe in the animals, as it did not affect blood pressure or heart rate.

In 2002 the first microparticle formed from an NO releasing polymer was reported by the Meyerhoff group [155]. The group deployed methyl methacrylate as an amine bearing monomer, and utilized 1,6-hexanedioldimethacrylate as a reactive cross-linker to form polymeric microbeads. The secondary amine groups were then converted to diazeniumdiolates to form NO releasing particles with a size of 100-200 µm. The particles had t_{1/2} values for NO release ranging from 30 to 60 min when suspended in PBS [155]. Following this initial work there has been an extensive effort to develop tunable release polymers for the controlled delivery of NO. For example GSNO was covalently attached to a diblock copolymer made from the polymerization of oligoethylene glycol-methacrylate (OEG-MA) and (4-cyanopentanoic acid)-4-dithiobenzoate to afford an NO releasing polymer, which in aqueous environments self-assembled and made nano-sized micelles. The polymeric NPs improved the stability of GSNO (3.5 fold) without affecting the efficacy of intracellular delivery. Additionally, in the presence of ascorbic acid, the t_{1/2} of the NPs was significantly longer than the GSNO alone, demonstrating protection from S-nitrosothiol degradation pathways. When neuroblastoma cells were pre-treated with these NO releasing NPs they were significantly more sensitive to cisplatin treatment, with a 5-fold shift in IC_{50}.

The use of dendrimers for controlled NO delivery was first described by the Schoenfisch group [156]. They used the commercially available generation 3 and 5 polypropylenimine dendrimers, and reacted them with high pressure gaseous NO (5 atm) to form NONOate dendrimers. NONOate
dendrimers generated from primary amines were not effective in providing sustained release of NO. However secondary amine NONOate dendrimers showed a high storage capacity for NO, and the release durations were significantly longer compared to small molecule alkyl secondary amine NONOates; however, the $t_{1/2}$ of most of the NO releasing dendrimers were less than 2 h [156]. In another study from the same group, generation 4 polyamidoamine (PAMAM) dendrimers were functionalized with either SNAP or N-acetyl-L-cysteine to yield thiol terminated dendrimers, then converted to SNT terminated dendrimers [157]. Similarly to low molecular weight SNTs, the kinetics of NO release were found to be highly sensitive to Cu$^+$ and photoactivation. The SNAP-dendrimer was particularly effective, showing 62% inhibition of platelet aggregation, which was almost 3 times greater than SNAP alone [157].

Gold nanoparticles (GNPs) have been widely used as non-toxic carriers in drug and gene delivery systems [158]. The inert and non-toxic gold core [159] and facile synthesis of GNPs make them very popular agents for drug delivery [158]. Rothrock et al. initially used GNPs for the controlled delivery of NO [160]. The synthesis strategy is shown in Fig. (7), approximately 2 nm diameter GNPs were made by reduction of tetrachloroaurate ($\text{AuCl}_4^-$) with sodium citrate or sodium borohydride in the presence of hexanethiol ligands. Then the ligands were exchanged with bromoalkane thiols, followed by reaction with ethylenediamine, butylamine or hexanediamine. When the GNPs (functionalized with a primary or secondary amine) were exposed to high pressure gaseous NO, the final NO-releasing NPs were generated [160]. Theoretically an advantage of these NO-releasing NPs is the ability to control both the amount of loaded NO, and the kinetics of NO release, by modification of the amount and/or structure of amine groups in the NPs [130]. However, due to the poor NO storage capacity and low solubility in aqueous media, the application of this class of NO-releasing NPs is limited [130].

Zeolites are aluminosilicate minerals which contain a variety of pore sizes and shapes [161], while metal-organic frameworks (MOFs) are a polymeric material consisting of metal ions bridged by organic ligands [162]. These classes of highly porous materials have been widely used for

Fig. (6). The NO releasing NP SNO-HSA-dimer enhanced the EPR effect of macromolecules in tumor tissue, and hence augmented the anti-tumor effects of the Dox loaded NP Doxil.
ion exchange, catalysis, and gas adsorption [161, 162]. The chemical characteristics of these materials, especially nano-scaled systems, make them potentially suitable for medical applications including the delivery of NO [163]. In zeolites, NO is chemisorbed to the cationic centers of the crystals [130], while in MOFs it can chemisorb to either the cationic centers or the organic structure of the framework. MOFs are well known for their high porosity and large surface areas, which gives them the capability of storing and delivering gases such as NO via physisorbing (physically trapping) within their pores [164, 165]. The physiochemical properties of MOFs (such as the level of porosity) can remarkably affect their control over NO delivery [166-168]. In general, the biomedical application of most zeolites and MOFs is restricted due to their low water solubility and instability [130].

More recently, stimuli responsive NO delivery has been utilized to control NO release on demand and in tumor tissue. For example, light responsive NO releasing NPs were made from the encapsulation of N,N′-di-sec-butyl-N,N′-dinitroso-1,4-phenylenediamine (BNN6), a NO releasing molecule, Dox and a mPEG-PLGA copolymer (Fig. 8) [169]. Upon the irradiation by UV light the NO content of BNN6 was released, and the generated NO gas broke the nanoparticle shell and led to the release of Dox. Hence, the release of both NO and Dox was responsive to UV irradiation. Incubation of OVCAR-8/ADR cells with the NPs resulted in a higher intracellular concentration of Dox compared to the equivalent treatment with free Dox, potentially due to NO release from the NPs inhibiting MDR [169]. In addition, other sources of energies (e.g. NIR, X rays and ultrasound) have been used to tune the NO release and anticancer properties of the NPs [170-172] as summarized in Table 2.

**CONCLUSION AND FUTURE PERSPECTIVES**

As detailed above, NO plays a key role in tumor biology and therapy, and there are several approaches that have been utilized to induce antitumor activities, or improve the efficacy of chemotherapy and radiotherapy, from NO releasing compounds. So far at least 16 families of NO precursor and NO donor functional groups have been developed. However only organic nitrates and SNP have clinical applications, predominantly for cardiovascular disease. Hence the development of stable and tuned NO donor compounds is a priority for drug discovery programs. Nanotechnology has revolutionized the NO delivery field, and the level of interest in NO releasing NPs has exploded over last decade. By protecting polymers carrying NO releasing functional groups from hydrolysis,
researchers have developed stable and controllable NO donors with superior biological functions, paving the way for their therapeutic applications towards a wide range of diseases including cancer.

However, the controlled delivery of cytotoxic levels of NO to tumor tissues remains a major challenge. Therefore, similarly to the hybrid NO donor drugs, investigations into NO releasing NPs have recently shifted to using them as an approach to strengthen the efficacy of existing drugs. Here NO delivery can inhibit MDR and potentiate the efficacy of chemotherapeutic drugs (recently reviewed [173-183]). Furthermore, the use of NO releasing nanocarriers can sensitize hypoxic cells to radiation, circumventing radiation resistance, which is a major hurdle in treating solid tumors [127].

**LIST OF ABBREVIATIONS**

| Abbreviation | Definition |
|--------------|------------|
| AMN          | Amyl nitrite |
| AuCl₄⁻       | Tetrachloroaurate |
| BNN6         | N,N’-di-sec-butyl-N,N’-dinitroso-1,4-phenylenediamine |
| cGMP         | Cyclic guanosine monophosphate |
| Cyt c        | Cytochrome c |
| DDS          | Drug delivery systems |
| DEA/NO       | Diethylamine NONOate |
| DETA/NO      | Diethylenetriamine NONOate |
| Dox          | Doxorubicin |
| Doxil        | Liposomal doxorubicin |
| EGFR         | Epidermal growth factor receptor |
| eNOS         | Endothelial NOS |
| EPR          | Enhanced permeability and retention |
| GNPs         | Gold nanoparticles |
| GSH          | Glutathione |
| GSNO         | S-nitrosoglutathione |
| GTN          | Glycerol trinitrate |
| HSA          | Human serum albumin |
| HSASNO       | S-nitrosated human serum albumin |
| IAMN         | Isoamyl nitrite |
| IC₅₀         | Inhibitory Concentration (50 %) |
| iNOS         | Inducible NOS |

**Fig. (8).** BNN6 is a NO releasing micelle which contains Dox. Upon photo-irradiation NO was released from BNN6, the nanoparticle shell broken, and Dox then released. In addition, the released NO significantly inhibited MDR (p-glycoprotein) and thereby resistance to Dox.
ISBN = Isobutyl nitrite
ISDN = Isosorbide dinitrate
ISMN = Isosorbide mononitrate
MAHMA/NO = Methylamine hexamethylene methyamine NONOate
MDR = Multi drug resistance
MOFs = Metal-organic frameworks
NADPH = Nicotinamide adenine dinucleotide phosphate
nNOS = Neuronal NOS
NO = Nitric oxide
NOS = Nitric oxide synthases
NP = Nanoparticle
OEG-MA = Oligoethylene glycol-methacrylate
PAMAM = Polyamidoamine
PETN = Pentaerythritol tetranitrate
PFC = Perfluorocarbon
Ph₃SNO = Trityl S-nitrosothiol
PKG = Protein kinase G
PLGA = Poly-lactic-co-glycolic acid
PROLI/NO = Proli NONOate
RNS = Reactive nitrogen species
ROS = Reactive oxygen species
RSH = Thiol
SIN-1 = 3-Morpholinosydnonimine
SMA = Styrene maleic acid
SNAP = S-nitroso-N-acetyl-DL-penicillamine
SNP = Sodium nitroprusside
SNT = S-nitrosothiol
SPER/NO = Spermine NONOate
STZ = Streptozocin
t₁/₂ = Half-life
TBME = Tert-butyl methyl ether
tButONO = Tert-butyl nitrite
tButSNO = Tert-butyl S-nitrosothiol
tDodSNO = Tert-dodecane S-nitrosothiol
VEGF = Vascular endothelial growth factor
ZnPP = Zinc protoporphyrin

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by (Arabian Gulf university research grant E003-PI-04/17) to KG. GIG was supported by a Laurenson Award from the Otago Medical Research Foundation.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Duong HT, Kamarudin ZM, Erlich RB, et al. Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers. Chem Comm 2013; 49(39): 4190-2.
[2] Wang PG, Xian M, Tang X, et al. Nitric oxide donors: chemical activities and biological applications. Chem Rev 2002; 102(4): 1091-134.
[3] Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology (Nobel lecture). Angew Chem Int Ed 1999; 38(13-14): 1882-92.
[4] Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109-42.
[5] Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30(1): 535-60.
[6] Shaw AW, Vosper AJ. Solubility of nitric oxide in aqueous and nonaqueous solvents. J Chem Soc, Faraday Trans 1 1977; 73: 1239-44.
[7] Malinski T, Taha Z, Grunfeld S, Patton S, Kapturczak M, Tomboulian P. Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors.
Biochim Biophys Res Commun 1993; 193(3): 1076-82.

[8] Moller MN, Denicola A. Diffusion of nitric oxide and oxygen in lipoproteins and membranes studied by pyrene fluorescence quenching. Free Radical Bio Med 2018; 128: 137-43.

[9] Choudhari SK, Chaudhary M, Bagde S, Gadbai AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol 2013; 11(1): 118.

[10] Lincoln J, Hoyle CH, Burnstock G. Nitric oxide in health and disease: Burnstock, Cambridge University Press: Cambridge, 1997.

[11] Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19(5): 711-21.

[12] Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Bio Med 1999; 25(4): 434-56.

[13] Maruyama K, Zhang E, Maruyama J. Clinical application of inhaled nitric oxide. In: Yoshikawa T, Naito Y, Eds. Gas Biology Research in Clinical Practice. Karger Publishers: Basel, Switzerland 2011; pp. 43-55.

[14] Wu HW, Li ZG, Liu G, Lu GZ, Liang HY. Effect of nitric oxide inhalation for the treatment of neonatal pulmonary hypertension. Eur Rev Med Pharmac 2016; 20(21): 4607-11.

[15] Troncy E, Francoeur M, Blaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anesth 1997; 44(9): 973-88.

[16] Cooper CE. Nitric oxide and iron proteins. Biochim Biophys Acta 1999; 1411(2): 290-309.

[17] Martin E, Davis K, Bian K, Lee Y, Murad F, editors. Cellular signaling with nitric oxide and cyclic guanosine monophosphate. Semin Perinatol 2000; 24(1): 2-6.

[18] Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Mitchell JB. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci USA 2004; 101(24): 8894-9.

[19] Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis in response to hypoxia. Proc Natl Acad Sci USA 2005; 102(37): 13472-5.

[20] Wink DA, Hines HB, Cheng RY, et al. Nitric oxide and redox mechanisms in the immune response. J Leuk Biol 2011; 89(6): 873-91.

[21] Thomas DD, Espey MG, Ridnour LA, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004; 101(24): 8894-9.

[22] Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1999; 1411(2): 351-69.

[23] Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995; 369(2-3): 136-9.

[24] Bal-Price A, Brown GC. Nitric-oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondrial oxidation. J Neurochem 2000; 75(4): 1455-64.

[25] Heller R, Polack T, Gräbner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of eNOS. Atherosclerosis 1999; 144(1): 49-57.

[26] Kanamaru Y, Takada T, Saura R, Mizuno K. Effect of nitric oxide on mouse clonal osteogenic cell, MC3T3-E1, proliferation in vitro. Kobe J Med Sci 2001; 47(1): 1-12.

[27] Xie K, Huang S, Dong Z, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181(4): 1333-43.

[28] Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. The Lancet Oncol 2001; 2(3): 149-56.

[29] Zhang R, Ma A, Urbanski SJ, McCaffery D-M. Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma. Carcinogenesis 2006; 28(5): 1122-30.
Controlled Delivery of Nitric Oxide for Cancer Therapy

Pharmaceutical Nanotechnology, 2019, Vol. 7, No. 4 299

[40] Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett 2014; 353(1): 1-7.

[41] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6): 1420-8.

[42] Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008; 104(3): 733-44.

[43] Bonavida B, Baritaki S, editors. Inhibition of epithelial-to-mesenchymal transition (EMT) in cancer by nitric oxide: pivotal roles of nitrosylation of NF-κB, YY1 and Snail. For Immunopathol Dis Therap 2012; 3(2): 125-33.

[44] Pan X, Wang X, Lei W, et al. Nitric oxide suppresses transforming growth factor-β1-induced epithelial-to-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2009; 50(5): 1577-87.

[45] Powan P, Chanvorachote P. Nitric oxide mediates cell aggregation and mesenchymal to epithelial transition in anoikis-resistant lung cancer cells. Mol Cell Biochem 2014; 393(1-2): 237-45.

[46] Jain KK. Drug Delivery Systems. Springer Science and Business Media: Switzerland 2008.

[47] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerf 2010; 75(1): 1-18.

[48] Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 2017; 1(1): 22-30.

[49] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.

[50] Vaapel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9(Supp 5): 4-9.

[51] Secomb TW, Hsu R, Park EY, Dewhirst MW. Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng 2004; 32(11): 1519-29.

[52] Dewhirst M, Ong E, Braun R, et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 1999; 79(11-12): 1717.

[53] Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8(6): 425-37.

[54] Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.

[55] Vaapel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Med Oncol 2001; 18(4): 243-59.

[56] Gacche RN. Compensatory angiogenesis and tumor refractoriness. Oncogenes 2015; 4: e153.

[57] Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56(4): 751-7.

[58] Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release 2012; 164(3): 265-75.

[59] Maeda H, Wu J, Sawat M, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65(1): 271-84.

[60] Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63(3): 136-51.

[61] Iyer AK, Khaleed G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11(17): 812-8.

[62] Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998; 58(1): 159-65.

[63] Akaike T, Horie H, Noguchi Y, et al. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996; 77(8): 1598-604.

[64] Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antigens to tumors by nitroglycerin application. Cancer Sci 2009; 100(12): 2426-30.

[65] Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol 2015; 6: 334-43.

[66] Lind M, Hayes A, Caprnda M, et al. Inducible nitric oxide synthase: Good or bad? Biomed Pharmacother 2017; 93: 370-5.

[67] Kubota M, Sakakihara Y, Mori M, Yamagata T, Momo-Yoshida M. Beneficial effect of L-arginine for stroke-like episode in MELAS. Brain Develop 2004; 26(7): 481-3.

[68] Finsterer J, Zarrour-Mahjoub S. A beneficial effect of L-arginine for stroke-like episodes is currently unsupported. Mol Genet Metab Rep 2018; 15: 67.

[69] Howell K, Costello CM, Sands M, Dooley I, McLoughlin P. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol-Lung C 2009; 296(6): 1042-50.

[70] Barbui A, Lazarou SA, Efron DT, Wasserkrug HL, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108(2): 331-6.

[71] Clement B, Schade D, Kotthaus J, inventors; Christian Albrechts Universitaet Kiel, assignee. N-o-hydroxy-L-arginine derivatives for the treatment of diseases. United States patent US 9,387,185. 2016.

[72] Reid KM, Tsung A, Kauzu T, et al. Liver I/R injury is improved by the arginase inhibitor, N-o-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol-Gastric Ln 2007; 292(2): 512-7.

[73] Münzel T, Steven S, Dabra A. Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vasc Pharmacol 2014; 63(3): 105-13.

[74] Schroder H. Cytochrome P-450 mediates bioactivation of organic nitrates. J Pharmacol Exp Ther 1992; 262(1): 298-302.
[75] McDonald BJ, Bennett BM. Biotransformation of glyceryl trinitrate by rat aortic cytochrome P450. Biochem Pharmacol 1993; 45(1): 268-70.

[76] Kenkare SR, Han C, Benet LZ. Correlation of the response to nitroglycerin in rabbit aorta with the activity of the mu class glutathione S-transferase. Biochem Pharmacol 1994; 48(12): 2231-5.

[77] Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76(2): 703-8.

[78] Hutter J, Schmidt M, Rittler J. Effects of sulphhydryl-containing compounds on nitroglycerin-induced coronary dilatation in isolated working rat hearts. Eur J Pharmacol 1988; 156(2): 215-22.

[79] Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Circ Res 2002; 90(1): 21-8.

[80] Thompson A. Counselling in practice: Glyceryl trinitrate for acute angina. Australian Pharmacist 2016; 35(1): 46.

[81] Ahlner J, Andersson R, Torfgård K, Axelsson K. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 1991; 43(3): 351-423.

[82] Gardiner S, Compton A, Kemp P, Bennett T. Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylelholine, Bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-l-arginine methyl ester. Br J Pharmacol 1990; 101(3): 632-9.

[83] Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. The Lancet 1991; 338(8774): 1036-9.

[84] Gardiner S, Czapski G. Mechanism of the nitrosation of thiols and amines by oxygenated NO solutions: the demonstration of NO formation. J Cardiovasc Pharmacol 1994; 28(1): 22-9.

[85] Bauer JA, Nolan T, Fung HL. Vascular and haemodynamic responses to glyceryl trinitrate, acetylelholine, Bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-l-arginine methyl ester. Br J Pharmacol 1990; 101(3): 632-9.

[86] Williams R. Nitric oxide in biology: its role as a ligand. Chem Soc Rev 1996; 118(14): 3419-25.

[87] Cederqvist B, Persson MG, Gustafsson LE. Direct demonstration of NO formation in vivo from organic nitrates and nitrates, and correlation to effects on blood pressure and to in vitro effects. Biochem Pharmacol 1994; 47(6): 1047-53.

[88] Omar SA, Artieme E, Webb AJ. A comparison of organic and inorganic nitrates/nitrites. Nitric Oxide 2012; 26(4): 229-40.

[89] Bauer JA, Nolan T, Fung HL. Vascular and haemodynamic differences between organic nitrates and nitrates. J Pharmacol Exp Ther 1997; 280(1): 326-31.

[90] Lim MH, Lippard SJ. Metal-based turn-on fluorescent probes for sensing nitric oxide. Acc Chem Res 2007; 40(1): 41-51.

[91] Tinker JH, Michenfelder JD. Sodium nitroprusside: pharmacology, toxicology and therapeutics. Anesthesiology 1976; 45(3): 340-54.

[92] Amaranath L, Kellermeyer WF. Tachyphylaxis to sodium nitroprusside. Anesthesiology 1976; 44(4): 345-8.

[93] Perschau RA, Modell JH, Bright RW, Shirley PD. Suspected sodium nitroprusside-induced cyanide intoxication. Anesth Analg 1977; 56(4): 533-7.

[94] Fry NL, Mascharak PK. Photoactive ruthenium nitrosyls as NO donors: how to sensitize them toward visible light. Acc Chem Res 2011; 44(4): 289-98.

[95] Bezerra CW, da Silva SC, Gambardella MT, et al. Water π-donation in trans-tetraammineruthenum(II): effect on coordinated-water properties induced by a trans NO ligand. Inorg Chem 1999; 38(25): 5660-7.

[96] Mascharak PK. Recent progress in photoinduced NO delivery with designed ruthenium nitrosyl complexes. Adv Inorg Chem 2015; 67: 145-70.

[97] Miller M, Megson I. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151(3): 305-21.

[98] Morley D, Keefer LK. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993; 22: S3-9.

[99] Hrabie JA, Klose JR, Wink DA, Keefer LK. New nitric oxide-releasing zwitterion derivatives derived from polyamines. J Org Chem 1993; 58(6): 1472-6.

[100] Brilli RJ, Krafte-Jacobs B, Smith DJ, et al. Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension. J Appl Physiol 1997; 83(6): 1968-75.

[101] Laverly KS, Rhodes C, Megrail A, Epphiemer MJ. Anti-thrombotic technologies for medical devices. Adv Drug Deliv Rev 2017; 112: 2-11.

[102] Krausz A, Friedman AJ. Nitric oxide as a surgical adjuvant. Fut Sci OA 2015; 1(1).

[103] Diotati JG, Quyyumi AA, Hussain N, Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect. Thromb Haemost 1993; 70(4): 654-8.

[104] Maragos CM, Morley D, Wink DA, et al. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 1991; 34(11): 3242-7.

[105] Pearce CG, Najjar SF, Kapadia MR, et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radical Bio Med 2008; 44(1): 73-81.

[106] Hermann M, Kapiotis S, Hofbauer R, et al. Recent progress in photoinduced NO delivery with designed ruthenium nitrosyl complexes. Adv Inorg Chem 2015; 67: 145-70.

[107] Perschau RA, Modell JH, Bright RW, Shirley PD. Suspected sodium nitroprusside-induced cyanide intoxication. Anesth Analg 1977; 56(4): 533-7.

[108] Pearce CG, Najjar SF, Kapadia MR, et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radical Bio Med 2008; 44(1): 73-81.

[109] Hermann M, Kapiotis S, Hofbauer R, et al. Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett 1999; 445(1): 212-4.

[110] Blaylock MG, Cuthbertson BH, Galley HF, Ferguson NR, Webster NR. The effect of nitric oxide and peroxynitrite on apoptosis in human polymorphonuclear leukocytes. Free Radical Bio Med 1998; 25(6): 748-52.

[111] Feilisch M, Ostrouski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol Ther 1989; 14: S13-S22.

[112] Reden J. Molsidomine. Blood Vessels. 1990; 27(2-5): 282-94.
[110] Peng W, Hoidal JR, Farrukh IS. Regulation of Ca(2+)-activated K⁺ channels in pulmonary vascular smooth muscle cells: role of nitric oxide. J Appl Physiol 1996; 81(3): 1264-72.

[111] Megson IL, Webb DJ. Nitric oxide donor drugs: current status and future trends. Expert Opin Inv Drug 2002; 11(5): 587-601.

[112] Al-Sa'doni H, Ferro A. S-nitrosothiols as nitric oxide-donors: chemistry, biology and possible future therapeutic applications. Curr Med Chem 2004; 11(20): 2679-90.

[113] Williams DLH. The chemistry of S-nitrosothiols. Acc Chem Res 1999; 32(10): 869-76.

[114] Zhang C, Biggs TD, Devarie-Baez NO, Shuang S, Dong C, Xian M. S-Nitrosothiols: chemistry and reactions. Chem Comm 2017; 53(82): 11266-77.

[115] Giles NM, Kumari S, Gang BP, Yuen CW, Billaud EM, Giles GI. The molecular design of s-nitrosothiols as photodynamic agents for controlled nitric oxide release. Chem Biol Drug Des 2012; 80(3): 471-8.

[116] Adeghate E, Parvez SH. Nitric oxide and neuronal and pancreatic beta cell death. Toxicology 2000; 153(1-3): 143-56.

[117] Spinas GA. The dual role of nitric oxide in islet β-cells. Physiology 1999 14(2): 49-54.

[118] McGill AD, Zhang W, Wittbrodt J, Wang J, Schlegel HB, Wang PG. Para-Substituted N-nitroso-N-oxygenzenamine ammonium salts: a new class of redox-sensitive nitric oxide releasing compounds. Bioorgan Med Chem 2000; 8(2): 405-12.

[119] Hecker M, Vorhoff W, Bara AT, Mordvintcev PI, Busse R. Characterization of furoxans as a new class of tolerance-resistant nitrosodiazos. Naunyn Schmiedebergs Arch Pharmacol 1995; 351(4): 426-32.

[120] Bohn H, Brendel J, Martorana PA, Schonafinger K. Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor. Br J Pharmacol 1995; 114(8): 1605-12.

[121] Serafim RA, Pernichelle FG, Ferreira EI. The latest advances in the discovery of nitric oxide hybrid drug compounds. Exp Opin Drug Discov 2017; 12(9): 941-53.

[122] Bandarage UK, Chen L, Fang X, et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem 2000; 43(21): 4005-16.

[123] Turnbull CM, Cena C, Fruttero R, Gasco A, Rossi AG, Megson IL. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br J Pharmacol 2006; 148(4): 517-26.

[124] Tesei A, Zoli W, Fabbri F, et al. NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. Nitric Oxide 2008; 19(2): 225-36.

[125] Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans 2005; 33(Pt 4): 701-4.

[126] Chegaev K, Riganti C, Lazzarato L, et al. Nitric oxide donor doxorubicins accumulate into doxorubicin-resistant human colon cancer cells inducing cytotoxicity. ACS Med Chem Lett 2011; 2(7): 494-7.

[127] Chegaev K, Fraix A, Gazzano E, et al. Light-regulated NO release as a novel strategy to overcome doxorubicin multidrug resistance. ACS Med Chem Lett 2017; 8(3): 361-5.

[128] Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27(32): 5459-68.

[129] Duan W, Li J, Inks ES, et al. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonfylfuroxan module as a nitric oxide donor. J Med Chem 2015; 58(10): 4325-38.

[130] Riccio DA, Schoenfisch MH. Nitric oxide release: part I. Macromolecular scaffolds. Chem Soc Rev 2012; 41(10): 3731-41.

[131] Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev 2012; 41(10): 3742-52.

[132] Coneski PN, Schoenfisch MH. Nitric oxide release: part III. Measurement and reporting. Chem Soc Rev 2012; 41(10): 3753-8.

[133] Wilcox DT, Glick PL, Karamanoukian HL, Leach C, Morin FC, Fuhrman BP. Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model. Crit Care Med 1995; 23(11): 1858-63.

[134] Tao Z, Ghoroghchian PP. Microparticle, nanoparticle, and stem cell-based oxygen carriers as advanced blood substitutes. Trends Biotechnol 2014; 32(9): 466-73.

[135] Raffikova O, Sokolova E, Rafikov R, Nudler E. Control of plasma nitric oxide bioactivity by perfluorocarbons. Circulation 2004; 110(23): 3573-80.

[136] Calavieri F, Finelli I, Tortora M, et al. Polymer microbubbles as diagnostic and therapeutic gas delivery device. Chem Mater 2008; 20(10): 3254-8.

[137] Huang S-L, Kee PH, Kim H, et al. Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia. Am J Cardio 2009; 54(7): 652-9.

[138] Gomes AJ, Barbougli PA, Espreafico EM, Tfouni E. Trans-[Ru(NO)NH34(py)](BF4)3.H2O encapsulated in PLGA microparticles for delivery of nitric oxide to B16-F10 cells: Cytotoxicity and phototoxicity. J Inorg Biochem 2008; 102(23): 3577-73.

[139] Bohlender C, Landfester K, Crespy D, Schiller A. Unconventional non-aqueous emulsions for the encapsulation of a phototiggerable NO donor complex in polymer nanoparticles. Part Part Syst Char 2013; 30(2): 138-42.

[140] Suchyta DJ, Schoenfisch MH. Controlled release of nitric oxide from liposomes. ACS Biomater Sci Eng 2017; 3(9): 2136-43.

[141] Suchyta DJ, Schoenfisch MH. Encapsulation of N-diaziniumdilates within liposomes for enhanced nitric oxide donor stability and delivery. Mol Pharmaceut 2015; 12(10): 3569-74.
[142] Alimoradi H, Barzegar-Fallah A, Sammut IA, Greish K, Giles G. Encapsulation of tDodsNO generates a nitric oxide releasing nanoparticle. Free Radical Bio Med 2019; 130: 297-305.

[143] Alimoradi H, Barzegar-Fallah A, Sammut IA, Greish K, Giles GI. Data characterizing the biophysical and nitric oxide release properties of the tDodsNO - styrene maleic anhydride nanoparticle SMA-tDodsNO. Data Brief 2018; 21: 1771-5.

[144] Alimoradi H, Greish K, Barzegar-Fallah A, Alshaibani L, Pittala V. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity. Int J Nanomed 2018; 13: 7771.

[145] Tahara Y, Yoshikawa T, Sato H, et al. Encapsulation of a nitric oxide donor into a liposome to boost the enhanced permeation and retention (EPR) effect. Med Chem Comm 2017; 8(2): 415-21.

[146] Quinn JF, Whittaker MR, Davis TP. Delivering nitric oxide with nanoparticles. J Control Rel 2015; 205: 190-205.

[147] de Mel A, Murad F, Seifalian AM. Nitric oxide: a guardian for vascular grafts? Chem Rev 2011; 111(9): 5742-67.

[148] Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14(10): 1014.

[149] Kudo S, Nagasaki Y. A novel nitric oxide-based anti-cancer therapeutics by macrophage-targeted poly (L-arginine)-based nanoparticles. J Control Release 2015; 217: 256-62.

[150] Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89(16): 7674-7.

[151] Ishima Y. Albumin-based nitric oxide traffic system for the treatment of intractable cancers. Biol Pharm Bull 2017; 40(2): 128-34.

[152] Matsushita S, Chuang VTG, Kanazawa M, et al. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin. Pharm Res 2006; 23(5): 882-91.

[153] Ishima Y, Chen D, Fang J, et al. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. Bioconjugate Chem 2012; 23(2): 264-71.

[154] Kinoshita R, Ishima Y, Ikeda M, et al. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes. J Control Release 2015; 217: 1-9.

[155] Parzuchowski PG, Frost MC, Meyerhoff ME. Synthesis and characterization of polymethacrylate-based nitric oxide donors. J American Chem Soc 2002; 124(41): 12182-91.

[156] Stasko NA, Schoenfisch MH. Dendrimers as a scaffold for nitric oxide release. J American Chem Soc 2006; 128(25): 8265-71.

[157] Stasko NA, Fischer TH, Schoenfisch MH. S-nitrosothiol-modified dendrimers as nitric oxide delivery vehicles. Biomacromolecules 2008; 9(3): 834-41.

[158] Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008; 60(11): 1307-15.

[159] Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005; 1(3): 325-7.

[160] Rothrock AR, Donkers RL, Schoenfisch MH. Synthesis of nitric oxide-releasing gold nanoparticles. J American Chem Soc 2005; 127(26): 9362-3.

[161] Pavelic K, Hadzija M. Medical applications of zeolites. In: Scott M. Auerbach, Kathleen A. Carrado, Prabir KD. Handbook of Zeolite Science and Technology, 1st ed. CRC press: New York, USA 2003; pp.1143-74.

[162] James SL. Metal-organic frameworks. Chem Soc Rev 2003; 32(5): 276-88.

[163] Hinks NJ, McKinlay AC, Xiao B, Wheatley PS, Morris RE. Metal organic frameworks as NO delivery materials for biological applications. Micropor Mesopor Mat 2010; 129(3): 330-4.

[164] Xiao B, Wheatley PS, Zhao X, et al. High-capacity hydrogen and nitric oxide adsorption and storage in a metal-organic framework. J American Chem Soc 2007; 129(5): 1203-9.

[165] Nguyen JG, Tanabe KK, Cohen SM. Postsynthetic diazeniumdiolate formation and NO release from MOFs. Cryst Eng Comm 2010; 12(8): 2335-8.

[166] McKinlay AC, Xiao B, Wragg DS, Wheatley PS, Megson IL, Morris RE. Exceptional behavior over the whole adsorption-storage-delivery cycle for NO in porous metal organic frameworks. J American Chem Soc 2008; 130(31): 10440-4.

[167] Diring S, Wang DO, Kim C, et al. Localized cell stimulation by nitric oxide using a photoactive porous coordination polymer platform. Nat Commun 2013; 4: 2684.

[168] McKinlay A, Eubank J, Wuttke S, et al. Nitric oxide adsorption and delivery in flexible MIL-88 (Fe) metal-organic frameworks. Chem Mater 2013; 25(9): 1592-9.

[169] Fan J, He Q, Liu Y, et al. Light-responsive biodegradable nanomedicine overcomes multidrug resistance via NO-enhanced chemosensitization. ACS Applied Mater Interf 2016; 8(22): 13804-11.

[170] Zhang X, Tian G, Yin W, et al. Controllable generation of nitric oxide by near infrared-sensitized upconversion nanoparticles for tumor therapy. Adv Func Mater 2015; 25(20): 3049-56.

[171] Fan W, Bu W, Zhang Z, et al. X-ray radiation-controlled NO-release for on demand depth independent hypoxic radiosensitization. Angew Chem Int Ed Engl 2015; 54(47): 14026-30.

[172] Zhang K, Xu H, Jia X, et al. Ultrasound-triggered nitric oxide release platform based on energy trans-
formation for targeted inhibition of pancreatic tumor. ACS Nano 2016; 10(12): 10816-28.

[173] Kim J, Yung BC, Kim WJ, Chen X. Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release 2017; 263: 223-30.

[174] Han JY, Nam BH, Kim HY, Yoon SJ, Kim HT, Lee JS. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capectabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer. Ann Oncol 2012; 23(11): 2925-30.

[175] Illum H, Wang DH, Dowell JE, et al. Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer. Surgery 2015; 158(2): 460-5.

[176] Yasuda H, Yamaya M, Nakayama K, et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006; 24(4): 688-94.

[177] Arrieta O, Blake M, de la Mata-Moya MD, et al. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer. Radiother Oncol 2014; 111(2): 311-5.

[178] Reinmuth N, Meyer A, Hartwigsen D, et al. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer 2014; 83(3): 363-8.

[179] Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009; 74(4): 878-83.

[180] Liu YS, Chuang MT, Tsai YS, Tsai HM, Lin XZ. Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention. European Radiol 2012; 22(10): 2193-200.

[181] Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 2010; 7(3): 775-85.

[182] Munaweera I, Shi Y, Koneru B, et al. Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer. J Inorg Biochem 2015; 153: 23-31.

[183] Fan J, He Q, Liu Y, et al. Light-responsive biodegradable nanomedicine overcomes multidrug resistance via no-enhanced chemosensitization. ACS App Mater Interf 2016; 8(22): 13804-11.